

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




AN

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 9/00, A61F 5/41, A61M 31/00</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/28142</b> (43) International Publication Date: 19 September 1996 (19.09.96)
---	-----------	--

(21) International Application Number: <b>PCT/US96/03086</b>	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>7 March 1996 (07.03.96)</b>	
(30) Priority Data: <b>08/403,333 14 March 1995 (14.03.95) US</b>	
(71) Applicant: VIVUS, INCORPORATED [US/US]; Suite 200, 545 Middlefield Road, Menlo Park, CA 94025 (US).	
(72) Inventor: PLACE, Virgil, A.; 10 Ala Kahua, P.O. Box 44555, Kawaihae, HI 96743 (US).	
(74) Agents: REED, Dianne, E. et al.; Reed & Robins, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).	

(54) Title: METHOD AND KIT FOR PREVENTING ERECTILE DYSFUNCTION



(57) Abstract

A method is provided for preventing erectile dysfunction, particularly vasoconstrictive impotence, in a male individual. The method involves periodic administration of a vasoactive agent throughout a 24-hour period. The agent and dosage regimen are selected such that regular increased blood flow to the penis is achieved, in turn preventing arterial occlusion and vascular deterioration of the muscular fibers of the vessels and collagen fibers of the cavernosal tissue.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5        METHOD AND KIT FOR PREVENTING ERECTILE DYSFUNCTIONTechnical Field

10        This invention relates generally to the administration of androgenic agents. More particularly, the invention relates to compositions and drug delivery systems for administering an androgenic agent such as testosterone to the mucosa of the oral cavity.

15        Background

Impotence is the consistent inability to achieve or sustain an erection of sufficient rigidity for sexual intercourse. It has recently been estimated that approximately 10 million American men 20 are impotent (R. Shabsigh et al., "Evaluation of Erectile Impotence," Urology 32:83-90 (1988); W.L. Furlow, "Prevalence of Impotence in the United States," Med. Aspects Hum. Sex. 19:13-6 (1985)). Impotence is recognized to be an age-dependent disorder, with an incidence of 1.9 percent at 40 years 25 of age and 25 percent at 65 years of age (A.C. Kinsey et al., "Age and Sexual Outlet," in Sexual Behavior in the Human Male, A.C. Kinsey et al., eds., Philadelphia, PA: W.B. Saunders, 218-262 (1948)). In 30 1985 in the United States, impotence accounted for more than several hundred thousand outpatient visits to physicians (National Center for Health Statistics, National Hospital Discharge Survey, 1985, Bethesda, MD, Department of Health and Human Services, 1989 DHHS publication no. 87-1751). Depending on the nature and 35 cause of the problem, treatments include psychosexual therapy, hormonal therapy, administration of vasodilators such as nitroglycerin and  $\alpha$ -adrenergic

blocking agents ("α-blockers"), oral administration of other pharmaceutical agents, vascular surgery, implanted penile prostheses, vacuum constriction devices and external aids such as penile splints to support the penis or penile constricting rings to alter the flow of blood through the penis.

A number of causes of impotence have been identified, including vasculogenic, neurogenic, endocrinologic and psychogenic. Impotence can also be a side effect of various classes of therapeutic drugs, or can be associated with various diseases, including diabetes, multiple sclerosis and sickle cell anemia. Impotence resulting from any one of these causes can be exacerbated by additional factors such as cigarette smoking, a poor diet, or the like.

Vasculogenic impotence occurs either as a result of arterial occlusion--the obstruction of adequate blood flow to the penile arteries necessary for erection--or as a result of cavernovenous leakage, i.e., excess venal outflow. As explained by Krane et al., "Medical Progress: Impotence," The New England Journal of Medicine 321(24):1628-1639 (1989), alteration in the flow of blood to and from the penis is believed to be the most frequent organic cause of impotence.

The present invention obviates the need for treatment of erectile dysfunction in a number of cases, insofar as a method is now provided which will substantially prevent the occurrence of vasculogenic impotence. The method involves periodic administration of a vasoactive agent as will be described below, within the context of a predetermined dosing regimen effective to provide for regularly increased blood flow to the penis. The invention additionally relates to kits which may be used in conjunction with the novel prophylactic method.

Summary of the Invention

Accordingly, it is a primary object of the present invention to address the aforementioned need in the art, by providing a novel method for preventing the occurrence of erectile dysfunction.

It is another object of the invention to provide a method for preventing erectile dysfunction which involves administering to a patient, within the context of a predetermined dosing regimen, a selected vasoactive agent.

It is still another object of the invention to provide such a method in which the vasoactive agent is administered transurethrally.

It is yet another object of the invention to provide such a method in which the erectile dysfunction is vasculogenic impotence.

It is a further object of the invention to provide such a method in which the vasoactive agent is administered in conjunction with a transurethral permeation enhancer.

It is yet a further object of the invention to provide a kit which an individual patient may use to conduct the aforementioned method.

Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.

In a first aspect of the invention, a vasoactive agent is administered to a patient in the context of a predetermined dosing regimen, such that drug is administered periodically throughout a 24-hour period. The drug is preferably administered transurethrally. It has now been found that regular administration of such an agent, preferably transurethrally, is effective to substantially prevent vasculogenic impotence. While not wishing to be bound

by theory, it is proposed that periodic administration of a vasoactive drug, by regularly increasing blood flow to the penis, not only prevents arterial occlusion but also prevents vascular deterioration of the muscular fibers of the vessels and collagen fibers of the cavernosal tissue. It has also been found that administration of vasoactive agents in this manner may be conducted at doses which are lower than those which are normally necessary with such drugs, i.e., when used for their previously known indications.

In another aspect of the invention, a kit is provided to assist a patient in drug administration. Generally, the kit will include the following components: the drug to be administered; a device for administering the drug, e.g., a transurethral administration device; a sealed container housing the drug and device prior to use; and written instructions for drug administration. The kit may include a means for administering the drug at different doses, or it may include different drugs.

#### Brief Description of the Drawing

Figure 1 is an exploded view of one embodiment of a transurethral therapeutic device which may be used in conjunction with the present method.

#### Detailed Description of the Invention

Before describing the present invention in detail, it is to be understood that this invention is not limited to particular drugs or drug delivery systems, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus,

for example, reference to "a vasoactive agent" includes a mixture of two or more such drugs, reference to "a transurethral permeation enhancer" includes mixtures of two or more enhancers, and the  
5 like.

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.

The term "drug" or "pharmacologically active agent" as used herein is intended to mean a compound or composition of matter which, when administered to an organism (human or animal) induces a desired pharmacologic and/or physiologic effect by local and/or systemic action. As noted above, the  
10 15 pharmacologically active agents used in conjunction with the present invention are vasoactive agents.

The terms "transurethral" or "intraurethral" as used to specify the mode of administration of vasoactive are used interchangeably to refer to  
20 delivery of the drug into the urethra such that drug contacts and passes through the wall of the urethra and enters into the blood stream.

By "transdermal" drug delivery, applicant is using the term in its conventional sense, i.e., to  
25 indicate delivery of a drug by passage through the skin and into the blood stream. By "transmucosal" drug delivery, applicant intends delivery of a drug by passage of a drug through the mucosal tissue into the blood stream. Aspects of the invention which are described in the context of "transurethral" drug  
30 delivery, unless otherwise specified, can apply to transdermal or transmucosal delivery as well. That is, the compositions, systems, and methods of the invention, unless explicitly stated otherwise, should  
35 be presumed to be equally applicable with any one of these three modes of drug delivery.

"Penetration enhancement" or "permeation enhancement" as used herein relates to an increase in

the permeability of the skin or mucosal tissue to a selected pharmacologically active agent, i.e., so that the rate at which the drug permeates through the skin or mucosal tissue is increased. "Transurethral permeation enhancers" increase the permeability of the urethral wall to drugs administered as described herein.

"Carriers" or "vehicles" as used herein refer to carrier materials suitable for transurethral drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is nontoxic and which does not interact with other components of the composition in a deleterious manner.

By an "effective" amount of a drug or pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect.

In order to carry out the method of the invention, a selected vasoactive agent is administered periodically throughout a twenty-four hour period. Suitable vasoactive agents include, but are not limited to: nitrates such as nitroglycerin, isosorbide dinitrate, erythrityl tetranitrate, amyl nitrate, sodium nitroprusside, molsidomine, linsidomine chlorhydrate ("SIN-1") and S-nitroso-N-acetyl-d,L-penicillamine ("SNAP"); long and short acting  $\alpha$ -blockers such as phenoxybenzamine, dibenamine, doxazosin, terazosin, phentolamine, tolazoline, prazosin, trimazosin, alfuzosin, tamsulosin and indoramin; ergot alkaloids such as ergotamine and ergotamine analogs, e.g., acetergamine, braergoline, bromerguride, cianergoline, delorgotriile, disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotriile, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride and terguride; antihypertensive agents such as diazoxide, hydralazine and minoxidil;

vasodilators such as nimodepine, pinacidil,  
cyclandelate, dipyridamole and isoxsuprime;  
chlorpromazine; haloperidol; yohimbine; trazodone;  
naturally occurring prostaglandins such as PGE<sub>1</sub>, PGA<sub>1</sub>,  
5 PGB<sub>1</sub>, PGF<sub>1α</sub>, 19-hydroxy-PGA<sub>1</sub>, 19-hydroxy-PGB<sub>1</sub>, PGE<sub>2</sub>,  
PGA<sub>2</sub>, PGB<sub>2</sub>, 19-hydroxy-PGA<sub>2</sub>, 19-hydroxy-PGB<sub>2</sub>, PGE<sub>3</sub>,  
PGF<sub>3α</sub>; semisynthetic or synthetic derivatives of  
natural prostaglandins, including carboprost  
tromethamine, dinoprost tromethamine, dinoprostone,  
10 lipoprost, gemeprost, metenoprost, sulprostone and  
tiaprost; and vasoactive intestinal peptides.  
Prazosin, prostaglandin E<sub>1</sub> and prostaglandin E<sub>2</sub> are  
particularly preferred vasoactive agents for use in  
conjunction with the present method.

15 Additionally, simultaneous administration of  
two or more vasoactive agents may be desirable and may  
in some cases exhibit a synergistic effect. The  
combination of prazosin with prostaglandin E<sub>1</sub> has been  
found to be particularly advantageous in this regard;  
20 the latter drug appears to act a permeation enhancer  
for prazosin, i.e., it increases the rate at which  
prazosin permeates through the skin or mucosal tissue  
and enters the bloodstream.

The vasoactive agent will typically be  
25 administered in a pharmaceutical composition  
containing one or more selected carriers or excipi-  
ents, as noted above. Examples of suitable carriers  
for use herein include water, silicone, waxes,  
petroleum jelly, polyethylene glycol, propylene  
glycol, liposomes, sugars such as mannitol and  
30 lactose, and a variety of other materials. The  
composition may also include one or more permeation  
enhancers, i.e., compounds which act to increase the  
rate at which the selected drug permeates through the  
35 skin or mucosal tissue. Examples of suitable  
permeation enhancers include dimethylsulfoxide (DMSO),  
dimethyl formamide (DMF), N,N-dimethylacetamide (DMA),  
decylmethylsulfoxide (C<sub>10</sub>MSO), polyethylene glycol

monolaurate (PEGML), glycerol monolaurate, lecithin, the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, CA), alcohols, or the like.

The amount of vasoactive agent administered is selected to provide for regularly increased blood flow to the penis, such that arterial occlusion is prevented, as is vascular deterioration of the muscle fibers of the vessels and collagen fibers of the cavernosal tissue. Each individual dose is selected, in general, so as to produce tumescence, i.e., penile engorgement, but not necessarily rigidity. Suitable doses of selected drugs will be apparent to those skilled in the art, or may be deduced from the literature in combination with the teaching of the present disclosure. However, it should be noted that the selected drug is preferably administered 2 to 6 times in a twenty-four hour period. Generally, a lower dose of vasoactive agent will be required than is typically necessary for the usual indication of such a drug, i.e., as an antihypertensive agent or the like. For prazosin, for example, administration of 100 to 400 µg/dose, preferably 1 to 10 mg/day, most preferably 0.5 to 5 mg/day, is preferred. For other drugs, generally 25% to 50% of the indicated daily dosage for use as an antihypertensive agent is appropriate. See the Physicians' Desk Reference®, 48th Edition, Medical Economics Data Production Company (Montvale, New Jersey, 1994).

Transurethral administration of the drug is preferred although not essential. As explained in co-pending patent application Serial No. 07/514,397, entitled "Treatment of Erectile Dysfunction" (published internationally as WO91/16021), the disclosure of which is incorporated by reference herein, transurethral administration of a drug can be carried out in a number of different ways. For

example, the drug can be introduced into the urethra from a flexible tube, squ eze bottle, pump or aerosol spray. The drug may also be contained in coatings, pellets or suppositories which are absorbed, melted or 5 bioeroded in the urethra. In certain embodiments, the drug is included in a coating on the exterior surface of a penile insert. A preferred drug delivery device for administering a drug transurethrally is shown in Figure 1.

10 In Figure 1, a transurethral drug delivery device is shown generally at 10. The device comprises a transurethral inserter 11 having an easily graspable segment 12 that has opposing symmetrically concave surfaces 13 and 14 adapted to be held by two fingers. 15 Drug is contained within shaft 15, which is sized to fit within the urethra. A longitudinal plunger, the tip of which is seen at 16, is slidably insertable into the longitudinal bore contained within shaft 15. To extrude drug into the urethra, shaft 15 is inserted 20 into the urethra, and plunger tip 16 is pushed into segment 12. The inserter 11 is then removed. Prior to use, and during storage, the device is capped with elongate cap 17 which fits snugly over flange 18 at the proximal end of shaft 15. The cap 17 is provided 25 with a series of parallel ridges 19 to facilitate gripping of the cap and removal from inserter 11.

Although the configuration shown in Figure 1 is a preferred configuration, other inserter/container configurations can be used and any mechanism by which 30 a predetermined quantity of drug can be introduced from the inserter at a predetermined depth in the urethra is suitable for use with this invention. Examples of other such devices are those described and illustrated in WO91/16021, incorporated by reference 35 above. The devices can either be manufactured under sterile conditions, thereby eliminating the need for post-manufacturing sterilization, or they can be manufactured under non-sterile conditions and then

subsequently sterilized by any suitable technique, e.g., radiation sterilization. The devices can be manufactured by typical plastic forming and coating processes known in the art, including molding extrusion, heat forming, dip coating, and the like.

5       The vasoactive agent may also be administered topically, transdermally or by any other available and effective means. Transdermal drug administration, as is well known to those skilled in 10 the art, involves the delivery of a pharmaceutical agent via percutaneous passage of the drug into the systemic circulation of the patient. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery: Fundamentals and Applications, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery of Drugs, Vols. 1-3, Kydonieus and Berner (eds.), CRC Press, (1987).

20       A variety of types of transdermal patches may be used in the method described herein. For example, a simple adhesive patch can be used which is prepared from a backing material and an acrylate adhesive. The adhesive layer is formulated so that 25 drug, and any carriers or enhancers which are to be used, are contained therein. Alternatively, a hydrogel matrix patch can be used in which drug, water and, typically, hydrophilic polymers, are used to form a hydrogel, which is then incorporated into a 30 transdermal patch between the backing and the adhesive layer. As will be appreciated by those skilled in the art, a number of other types of patch configurations can be used as well, including liquid reservoir patches, foam matrix patches, and the like. See, 35 e.g., U.S. Patent Nos. 3,598,122, 4,649,075 and 5,120,544, the disclosures of which are incorporated by reference herein.

Other components may be incorporated into such transdermal patches as well. For example, compositions and/or transdermal patches may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.

The invention also encompasses a kit for patients to carry out the aforementioned prophylactic method. The kit contains the drug to be administered, a device for administering the drug, preferably transurethrally (e.g., as shown in Figure 1), a sealed container housing the drug and device prior to use, and written instructions for drug administration. The kit may include a means for administering the drug at different doses, or it may include different drugs, or a combination thereof. (That is, if the drug as initially administered is not effective, incrementally higher doses of drug can be used, or alternative drugs may be administered.)

The method of the invention accordingly provides effective prophylactic therapy, in that the occurrence of erectile dysfunction, particularly vasculogenic impotence, is substantially prevented in most patients.

---

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the examples which follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

Example 1

Patients with a tendency toward vasculogenic impotence, such as patients who have recently undergone a radical prostatectomy, are given 0.3 mg prazosin hydrochloride every four hours throughout a 24-hour period. After several days to several weeks, various penile hemodynamic parameters are measured and compared with corresponding parameters evaluation prior to drug therapy. These parameters will typically include cavernosal artery peak systolic velocity, cavernosal artery end diastolic velocity, maximum arterial dilation, and pressure. Based on these measurements, a determination is made as to whether penile vascular sufficiency is present. It will be appreciated by those skilled in the art that any number of devices can be used to conduct the aforementioned measurements, providing that the desired level of accuracy is achieved. Duplex ultrasonography is the preferred mode of evaluating the penile hemodynamic parameters of interest. However, other types of techniques and equipment may be used as well, e.g., NMR spectroscopy, pressure cuffs, corpus cavernosograms, angiography, NPT (nocturnal penile tumescence) "Rigiscans," magnetic resonance imaging (MRI), computer aided tomography (CAT), pulsoximeters, and the like.

Examples of duplex ultrasonography devices which can be used in conjunction with the present method include those described in U.S. Patent Nos. 4,334,543 to Fehr, 4,485,821 to Iinuma, and 4,612,937 to Miller, the disclosures of which are incorporated by reference herein. Suitable devices are available from a number of manufacturers, including, for example, Advanced Technology Laboratories (Bothell, Washington) and Siemens Quantum (Issaquah, Washington).

Based on the hemodynamic parameters measured using the aforementioned ultrasonography technique, a

diagnosis can be made as to penile vascular sufficiency. Generally, if the measured PSV is less than about 50 cm/sec, more typically less than about 35 cm/sec, vascular inflow is insufficient, and a diagnosis of arterial insufficiency may be made.

5 Alternatively, or additionally, if the measured EDV is greater than 0 cm/sec, more typically greater than about 5 cm/sec, a diagnosis of venous leakage may be made. It is expected that after the aforementioned

10 drug therapy, the penile hemodynamic measurements which are conducted will lead to a finding of penile vascular sufficiency.

Example 2

15 The procedure of Example 1 is repeated, except that drug is administered every six hours instead of every four hours, with dosage adjusted accordingly. Substantially the same results are expected.

20

Example 3

The procedure of Example 1 is repeated, except that drug is administered every eight hours instead of every four hours, with dosage adjusted

25 accordingly. Substantially the same results are expected.

Example 4

30 The procedure of Example 1 is repeated, except that drug is administered every twelve hours instead of every four hours, with dosage adjusted accordingly. Substantially the same results are expected.

35

Example 5

The procedure of Example 1 is repeated, except that prazosin base is substituted for prazosin

hydrochloride. Substantially the same results are expected.

Example 6

5           The procedure of Example 5 is repeated, except that drug is administered every six hours instead of every four hours, with dosage adjusted accordingly. Substantially the same results are expected.

10

Example 7

15          The procedure of Example 5 is repeated, except that drug is administered every eight hours instead of every four hours, with dosage adjusted accordingly. Substantially the same results are expected.

Example 8

20          The procedure of Example 5 is repeated, except that drug is administered every twelve hours instead of every four hours, with dosage adjusted accordingly. Substantially the same results are expected.

25

Example 9

The procedure of Example 1 is repeated, except that prostaglandin E<sub>1</sub> is substituted for prazosin, at a dose of approximately 3.0 µg/kg body weight. Substantially the same results are expected.

30

Example 10

35          The procedure of Example 9 is repeated, except that drug is administered every six hours instead of every four hours, with dosage adjusted accordingly. Substantially the same results are expected.

Example 11

The procedure of Example 9 is repeated,  
except that drug is administered every eight hours  
instead of every four hours, with dosage adjusted  
5 accordingly. Substantially the same results are  
expected.

Example 12

10 The procedure of Example 9 is repeated,  
except that drug is administered every twelve hours  
instead of every four hours, with dosage adjusted  
accordingly. Substantially the same results are  
expected.

15

Example 13

The procedure of Example 1 is repeated,  
except that prostaglandin E<sub>2</sub> is substituted for  
prazosin, at a dose of approximately 5 mg.  
Substantially the same results are expected.

20

Example 14

The procedure of Example 13 is repeated,  
except that drug is administered every six hours  
instead of every four hours, with dosage adjusted  
25 accordingly. Substantially the same results are  
expected.

Example 15

30 The procedure of Example 13 is repeated,  
except that drug is administered every eight hours  
instead of every four hours, with dosage adjusted  
accordingly. Substantially the same results are  
expected.

35

Example 16

The procedure of Example 13 is repeated,  
except that drug is administered ev ry twelve hours  
instead of every four hours, with dosage adjusted

accordingly. Substantially the same results are expected.

5

10

15

20

25

30

35

Claims:

1. A method for preventing erectile dysfunction in a male individual, comprising  
5 administering a selected vasoactive agent to the individual within the context of a dosing regimen effective to provide for regularly increased blood flow to the penis.

10 2. The method of claim 1, wherein the vasoactive agent is administered transurethrally.

15 3. The method of claim 2, wherein the dosing regimen comprises administration of a predetermined dose of the vasoactive agent two to six times in a twenty-four hour period.

20 4. The method of claim 1, wherein the erectile dysfunction is vasculogenic impotence.

25 5. The method of claim 2, wherein drug administration is carried out by placing the vasoactive agent in contact with the male urethra at a location between the proximal portion of the fossa navicularis and the distal portion of the pendulous urethra, such that the drug enters the individual's blood stream through the urethral wall.

30 6. The method of claim 5, wherein the agent is administered in a dispersant which releases the agent in the urethra at said depth at a weight ratio of dispersant to agent of about 1:1 to 50:1, the amount of said dose not exceeding the dose retaining capacity of the urethra.

35 7. The method of claim 6, wherein the amount of agent and dispersant that is administered transurethrally is approximately 50 mg.

8. The method of claim 2, wherein a transurethral permeation enhancer is administered with the vasoactive agent.

5 9. The method of claim 8, wherein the transurethral permeation enhancer and vasoactive agent are administered simultaneously.

10 10. The method of claim 9, wherein the transurethral permeation enhancer and vasoactive agent are administered in a single pharmaceutical composition.

15 11. The method of claim 8, wherein the transurethral permeation enhancer and vasoactive agent are administered sequentially.

20 12. The method of claim 1, wherein the vasoactive agent is selected from the group consisting of antihypertensive agents, nitrates, long- and short-acting  $\alpha$ -blockers, calcium blockers, ergot alkaloids, chlorpromazine, haloperidol, yohimbine, natural and synthetic vasoactive prostaglandins and their analogs, vasoactive intestinal peptides, dopamine agonists, 25 opioid antagonists, and combinations thereof.

30 13. The method of claim 2, wherein the vasoactive agent is selected from the group consisting of antihypertensive agents, nitrates, long- and short-acting  $\alpha$ -blockers, calcium blockers, ergot alkaloids, chlorpromazine, haloperidol, yohimbine, natural and synthetic vasoactive prostaglandins and their analogs, vasoactive intestinal peptides, dopamine agonists, opioid antagonists, and combinations thereof.

35 14. The method of claim 13, wherein the vasoactive agent is an antihypertensive agent.

15. The method of claim 14, wherein the antihypertensive agent is prazosin.

16. The method of claim 13, wherein the  
5 vasoactive agent is prostaglandin E<sub>1</sub>.

17. The method of claim 13, wherein prazosin and prostaglandin E<sub>1</sub> are administered simultaneously.

10

18. A kit for preventing vasculogenic erectile dysfunction in a male individual, comprising:  
a vasoactive agent effective to increase blood flow to the penis; a drug delivery means for administering the  
15 vasoactive agent; a container for housing the agent and drug delivery means; and written instructions for using the agent and drug delivery means.

19. The kit of claim 18, wherein the  
20 vasoactive agent is selected from the group consisting of antihypertensive agents, nitrates, long- and short-acting α-blockers, calcium blockers, ergot alkaloids, chlorpromazine, haloperidol, yohimbine, natural and synthetic vasoactive prostaglandins and their analogs,  
25 vasoactive intestinal peptides, dopamine agonists, opioid antagonists, and combinations thereof.

20. The kit of claim 19, wherein the vasoactive agent is an antihypertensive agent.


30

21. The kit of claim 20, wherein the antihypertensive agent is prazosin.

22. The kit of claim 19, wherein the  
35 vasoactive agent is prostaglandin E<sub>1</sub>.

23. The kit of claim 19, containing prazosin and prostaglandin E<sub>1</sub>.

1/1



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/03086

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K9/00 A61F5/41 A61M31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 16021 (ALZA CORP) 31 October 1991 cited in the application see page 6, line 29 - line 32 see page 7, line 31 - page 8, line 2; claims 1-33	1-23
X	& US,A,5 242 391 (PLACE VIRGIL A ET AL) 7 September 1993 see column 5, line 44 - line 46	1-23
Y	US,A,5 059 603 (RUBIN DAVID) 22 October 1991 see column 5, line 46 - column 7, line 60	1-23
Y	EP,A,0 459 666 (PFIZER) 4 December 1991 see page 3, line 34 - page 4, line 25	1-23
A	EP,A,0 357 581 (AMSU LTD) 7 March 1990 see the whole document	1-23
	---	
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

1

Date of the actual completion of the international search

30 July 1996

Date of mailing of the international search report

20.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Foerster, W

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/03086

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 00894 (SCOTT NATHAN E) 21 January 1993 see the whole document -----	1-23

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International / National No	
PCT/US 96/03086	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9116021	31-10-91	AU-B-	655420	22-12-94
		AU-B-	7856391	11-11-91
		CA-A-	2040914	26-10-91
		EP-A-	0526566	10-02-93
		US-A-	5474535	12-12-95
		US-A-	5242391	07-09-93
US-A-5059603	22-10-91	NONE		
EP-A-0459666	04-12-91	AT-T-	113839	15-11-94
		AU-B-	620282	13-02-92
		AU-B-	7807791	05-12-91
		CA-A-	2043440	01-12-91
		DE-D-	69105040	15-12-94
		DE-T-	69105040	23-03-95
		IL-A-	98258	31-01-96
		JP-A-	4235917	25-08-92
		KR-B-	9310582	30-10-93
		US-A-	5270323	14-12-93
EP-A-0357581	07-03-90	SE-B-	463851	04-02-91
		AU-B-	638414	01-07-93
		AU-B-	4199489	02-04-90
		CA-A-	1335346	25-04-95
		DE-T-	68907909	23-12-93
		EP-A-	0432199	19-06-91
		ES-T-	2055677	01-09-94
		IE-B-	62587	08-02-95
		JP-B-	7091199	04-10-95
		JP-T-	4501707	26-03-92
		SE-A-	8803087	03-03-90
		WO-A-	9002545	22-03-90
WO-A-9300894	21-01-93	AU-B-	2300092	11-02-93